GelrinS / Platform Derivatives

About Regentis Biomaterials

Regentis Biomaterials specializes in creating advanced hydrogel implants for the repair and regeneration of damaged tissues, primarily in musculoskeletal and wound healing applications. The company's core technology involves a unique, light-activated hydrogel that polymerizes in situ to form a stable, biocompatible scaffold. Its most advanced program, GelrinC for cartilage repair, has progressed through clinical trials. Regentis operates as a publicly traded entity, leveraging its platform to target large, underserved markets in orthopedics.

Therapeutic Areas